



LUND UNIVERSITY

The coagulation system and its function in early immune defense.

van der Poll, T; Herwald, Heiko

Published in:
Thrombosis and Haemostasis

DOI:
[10.1160/TH14-01-0053](https://doi.org/10.1160/TH14-01-0053)

2014

[Link to publication](#)

Citation for published version (APA):
van der Poll, T., & Herwald, H. (2014). The coagulation system and its function in early immune defense. *Thrombosis and Haemostasis*, 112(4), 640-648. <https://doi.org/10.1160/TH14-01-0053>

Total number of authors:
2

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

1 **The coagulation system and its function in early**
2 **immune defense**

3
4 **Tom van der Poll¹ and Heiko Herwald^{2*}**

5
6
7 From the ¹Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam,
8 Netherlands and ²the Division of Infection Medicine, Department of Clinical
9 Sciences, Lund University, Biomedical Center, Tornavägen 10, SE-22184 Lund,
10 Sweden.

11
12
13
14
15 *To whom correspondence should be addressed: Department of Clinical
16 Sciences, Lund, Division of Infection Medicine, BMC B14, Lund University,
17 Tornavägen 10, SE-221 84 Lund, Sweden. Phone +46-46-2224182, Fax +46-46-
18 157756, e-mail heiko.herwald@med.lu.se

1 **Abstract**

2 Blood coagulation has a Janus-faced role in infectious diseases. When systemically
3 activated it can cause serious complications associated with high morbidity and
4 mortality. However, coagulation is also part of the innate immune system and its local
5 activation has been found to play an important role in the early host response to
6 infection. Though the latter aspect has been less investigated, phylogenetic studies
7 have shown that many factors involved in coagulation have ancestral origins which
8 are often combined with anti-microbial features. This review gives a general overview
9 about the most recent advances in this area of research also referred to as
10 immunothrombosis.

11

1 **Introduction**

2 Blood clotting is initiated only seconds after vascular injury which makes it one of the
3 fastest tissue repair systems in our body (1). Its main purpose, sealing an injured
4 vessel, is accomplished by an aggregation of platelets at the site of the lesion. This
5 will then lead to a loose platelet plug, which is further stabilized by the formation of a
6 fibrin network. Both events, also known as primary and secondary hemostasis, not
7 only help prevent the efflux of blood cells and plasma proteins into the surrounding
8 tissue, but also trigger wound healing and tissue regeneration processes. As bleeding
9 sites are potential ports of entry for microorganisms, coagulation is also one of the
10 first humoral regulatory systems that encounters an intruder. It therefore seems
11 plausible that during activation of coagulation, immune defense machineries are also
12 alerted and activated. This in turn should help diminish the risk of systemic microbial
13 invasion. In fact, mammals have established a manifold arsenal of defense
14 mechanisms which are mobilized when coagulation is activated. These include for
15 instance the release of antimicrobial peptides (AMPs) from platelets (2) or their
16 generation during clot formation (3). In addition, cellular responses are triggered; for
17 example an intact platelet-fibrinogen plug can provide an active surface that allows
18 the recruitment, attachment, and activation of phagocytizing cells (4) and many
19 coagulation factors are able to induce pro- and anti-inflammatory reactions by
20 activating so-called protease activated receptors (PAR) on immune cells (5). These
21 findings have lately attracted considerable attention and has led to a novel area of
22 research which is now referred to as “*immunothrombosis*” in the literature (6). The
23 present review aims to provide an overview of the role of the coagulation system in
24 the early immune response to bacterial infection (Figure 1).

25 **Hemostasis and inflammation**

26 Hemostasis and inflammation are tightly interwoven and can regulate each other in a
27 concert action when activated during infection (7). The efficacy to eradicate the
28 invading pathogen is to a great deal dependent on the amplitude of the coagulative
29 and inflammatory responses of the host. Both systems are normally down-regulated
30 under non-infectious conditions. However, as soon as an invading pathogen is sensed,
31 they can become activated and start initiating immune reactions and wound healing
32 processes. In order to guarantee an efficient elimination of the pathogen, the
33 amplitude of these responses has to be in a physiologically relevant range. Under
34

1 certain conditions, host control mechanisms can fail and systemic activation of
2 coagulation and inflammatory cascades can reach pathological dimensions. These
3 complications are combined with high morbidity and mortality and are almost
4 impossible to treat (8).

6 **Extrinsic pathway of coagulation**

7 Tissue factor (TF), also referred to as CD142 or thromboplastin, is a membrane-
8 spanning glycoprotein and the principal activator of the extrinsic pathway of
9 coagulation. The protein is constitutively expressed on many extravascular cells, such
10 as fibroblasts, pericytes, and epithelial cells, while it is found at low levels, or in an
11 encrypted form, on cells which are in constant contact with plasma proteins (9). Some
12 cell types such as monocytes and endothelial cells can up-regulate TF on their surface
13 under inflammatory conditions (10). Apart from its essential role in activating the
14 coagulation cascade, TF shares structural homology with class II cytokine receptors
15 (11) and can evoke a number of inflammatory reactions (12). It was as early as 1995
16 when it was reported for the first time that binding of factor VII to TF triggers the
17 mobilization of cytosolic calcium in many cell types (13). Today it is known that TF
18 can signal via a PAR-dependent and independent pathway involving two completely
19 different modes of action (14). The PAR-dependent pathway engages TF as a cofactor
20 and docking protein that is required for interaction of factors VII and X with PAR2
21 (15). The PAR-independent pathway on the other hand is activated by an alternatively
22 spliced form of TF which interacts with integrins and leads to an activation of
23 members of the mitogen activated protein kinase family (16). Both pathways have
24 been shown to evoke inflammatory responses such as the release of cytokines,
25 chemokines, and adhesion factors (17, 18). Activation of TF can be part of the host
26 defense to infection and a protective role for TF in infectious disease models was, for
27 instance, described by Deyan Luo and co-workers who published that mice with low
28 tissue factor activity succumb to yersiniosis (19). Although these findings point to a
29 critical role of TF in the host defense against *Yersinia enterocolitica*, TF is not an
30 interesting target for drug development as its systemic activation bears the risk of life-
31 threatening complications, as discussed later.

32 In addition to TF, its regulators are also involved in the early immune defense.
33 Papareddy and colleagues, for example, reported in 2010 that the carboxy-terminal
34 part of tissue factor pathway inhibitor 1 (TFPI-1) has antimicrobial properties that can

1 kill a number of pathogens including Gram negative (*Escherichia coli* and
2 *Pseudomonas aeruginosa*) and Gram-positive bacteria (*Bacillus subtilis* and
3 *Staphylococcus aureus*), as well as a number of fungal species (*Candida albicans* and
4 *Candida parapsilosis*) (20). The same authors reported that tissue pathway inhibitor 2
5 (TFPI-2), a homologue of TFPI-1, also explores antibacterial activity upon proteolytic
6 processing (21). TFPI-2 is a weak TF inhibitor, but it interacts with a wide range of
7 other coagulation factors and is up-regulated under inflammatory conditions (22, 23).

9 **Intrinsic pathway of coagulation**

10 In 2003, Esmon and Opal stated that the “pattern recognition molecules of the innate
11 immune system function in a manner that is remarkably similar to that of contact
12 factors of the intrinsic clotting system” (24). Indeed during the last two decades, the
13 list of bacterial pathogens that are recognized by the contact system is steadily
14 increasing and it includes all types of microorganisms (25). Contact activation at the
15 bacterial surface leads to the generation of bradykinin that is released from plasma
16 kallikrein-processed high-molecular weight kininogen. Bradykinin can be further
17 cleaved to des-Arg⁹-bradykinin (26). Both kinins are potent inflammatory mediators
18 with specific pharmacological profiles because they signal via distinct receptors.
19 Notably, the tissue distribution and physiological characteristics of the two receptors
20 show marked differences (27). While bradykinin binds to B2R, a receptor that is
21 constitutively expressed and involved in acute inflammatory reactions, des-Arg⁹-
22 bradykinin has higher affinity to B1R. In contrast to B2R, B1R is inducible and has
23 been found to evoke chronic inflammatory responses (27). B2R and B1R have been
24 implicated in the early defense against microorganisms. Monteiro and co-workers for
25 instance, employed a *Trypanosoma cruzi* infection model to show that the cooperative
26 activation of B2R and Toll-like receptor 2 is responsible for an interferon- γ response
27 in dendritic cells. These findings allowed the authors to conclude that bradykinin is
28 capable of linking innate and adaptive immune responses (28). Passos and colleagues
29 on the other hand, reported that LPS-induced up-regulation of B1R leads to a NF- κ B
30 mediated cytokine response followed by the recruitment of neutrophils (29). Together
31 these findings suggest that both kinins play an important role at different stages of the
32 host response to infection.

33 When activated by bacteria such as *Streptococcus pyogenes*, contact activation leads

1 to the release of kininogen-derived AMPs with a broad activity (3). Other studies with
2 *Escherichia coli*, *Pseudomonas aeruginosa*, and *Enterococcus faecalis* have shown
3 that even more AMPs are generated when kininogens are further processed with
4 neutrophil elastase (30). A release of AMP from the other three contact factors
5 (plasma kallikrein, factor XI, and factor XII, respectively) has not been described. It
6 has been proposed that the antimicrobial activity of kininogens has resulted in a
7 different evolutionary pressure on kininogens compared to the other contact factors.
8 Cagliani and colleagues recently published a phylogenetic analysis showing no
9 consistent evidence of adaptive evolution for plasma kallikrein, factor XI, and factor
10 XII, while strong signatures of diversifying positive selection were detected for
11 kininogens (31). Based on their findings, the authors concluded that kininogens have
12 been a target of long-lasting and strong selective pressure, suggesting that kininogens
13 play a central role in the modulation of the innate immune response (31).

14 15 **The common pathway of coagulation**

16 The final step in the clotting cascade starts with the processing of fibrinogen by factor
17 X-activated thrombin. This will eventually lead to the formation of a fibrin clot which
18 is further stabilized by the action of factor XIII (32). Concomitantly, thrombin
19 activates protein C and thereby initiates repression of hemostasis (33). As mentioned
20 before, PAR receptors are an important link between coagulation and inflammation.
21 While factor X targets PAR1 and PAR2, thrombin can also activate PAR3. In both
22 cases, activation triggers pro-inflammatory reactions such as the inductions of IL-6,
23 IL-8, TGF- β , and monocyte chemoattractant protein-1 (34). The activation of PAR1
24 by activated protein C (APC) is more complicated and requires a docking protein,
25 endothelial protein C receptor or EPCR. In contrast to PAR1 activation by factor X or
26 thrombin, APC evokes anti-inflammatory reactions, including for instance inhibition
27 of leukocyte adhesion and maintaining endothelial barrier function (35). The
28 molecular mechanisms underlying different PAR1 signaling are not completely
29 understood but several modes of actions have been proposed as summarized by a
30 review article from Versteeg and colleagues (1). In addition to PAR1 activation, a
31 recent study has shown that APC cleaves and neutralizes extracellular histones in a
32 murine infection model thereby preventing lethality in these animals (36). Notably,
33 APC has been used as a treatment in patients suffering from severe infectious

diseases, but due to lack of efficiency it was withdrawn from the market in 2011 (37). Many coagulation factors, including factor X and thrombin, contain a sequence at their carboxyterminal region of the catalytic domain that explores antimicrobial activity when generated by proteolytic processing (38). In the case of thrombin, such a peptide was found to be released under *in vitro* and *in vivo* conditions (20) and when injected into mice the peptide was able to modulate inflammatory reactions and protect animals from endotoxin-induced shock (39). These findings suggest that coagulation factors, such as **prothrombin**, have more functions that are of importance in the host response to infection. Notably, phylogenetic analyses revealed that vertebrate coagulation factors, including factor X and thrombin, share ancestry with complement proteinases. It has therefore been concluded that blood clotting has emerged as a byproduct of the innate immune system (40). It is worth noting that fibrinogen-like proteins have also been described to have an important role in ancestral immunity. Proteins containing fibrinogen motifs have been found in numerous invertebrate organisms. While these proteins play a critical role in the immune response to infection, they are not involved in blood clotting. A role for fibrinogen in hemostasis has occurred evolutionary only recently, with the first description being in deuterostomes (41). In vertebrates, processing of fibrinogen leads to a number of immune reactions such as the release of antimicrobial peptides, chemotactic responses triggered by fibrinogen-derived peptides, and neutrophil recruitment and adhesion (4, 42, 43). Apart from triggering these immune reactions, fibrinogen when processed to fibrin, can also act as a physical barrier that entraps bacteria within a formed clot. Additional crosslinking of the captured microorganisms by the action of coagulation factor XIII, a transglutaminase, helps to immobilize the pathogen in the clot and prevent its further dissemination (44).

Procoagulant microparticles

Microparticles (MPs, also referred to as microvesicles or ectosomes) are vesicles measuring 0.1 to 2 μm that are shed from the plasma membrane of multiple cell types upon activation or apoptosis by a process that involves reorganization of the membrane lipid composition and the translocation of phosphatidylserine to the outer leaflet (45, 46). MPs lack a nucleus and express antigens of the cell from which they are derived, allowing investigations of the function of cell-specific MPs in various disease states. MPs represent a circulating pool of biologically active molecules,

1 containing proteins, messenger and microRNA's, as well as lipids; the MP content
2 may vary depending on cellular origin and disease state. Apart from exerting a large
3 variety of proinflammatory and procoagulant properties, they can also function to
4 transfer biological information between cells and organs. MPs can be detected at low
5 levels in the circulation of healthy individuals, predominantly originating from
6 platelets, where they induce low grade thrombin generation (47). Upon disruption of
7 the integrity of the vascular endothelial barrier, platelet-derived MPs are important for
8 primary hemostasis. The outer surface of MPs is enriched in phosphatidylserine,
9 which provides a catalytic surface for the assembly of contact factors and vitamin K-
10 dependent enzyme complexes of the coagulation system (factors VII, IX, X and
11 thrombin) (45, 46, 48). While intact platelets are essential for triggering blood
12 coagulation, platelet MPs offer an additional phospholipid platform that has
13 approximately 50-100-fold more procoagulant activity (49). Moreover, MPs are the
14 most important reservoir for blood-borne TF. MPs can transfer and deliver TF to
15 target cells, including platelets and neutrophils, thereby amplifying and disseminating
16 the procoagulant response. As such, notwithstanding their physiological role in the
17 prevention of bleeding, abundant release of procoagulant MPs clearly can contribute
18 to thrombotic events. Mice deficient for lactadherin, an opsonin that is important for
19 the clearance of platelet MPs, have elevated concentrations of circulating MPs and
20 produced two-fold more thrombin (50). Importantly, lactadherin-deficient mice had a
21 shorter venous occlusion time in an endothelial cell injury model, indicating that
22 impaired clearance of platelet MPs results in a hypercoagulable state (50). In
23 accordance, platelet MPs contributed to thrombus growth in a mouse model of venous
24 thrombosis (51).

25 Bacterial agonists and proinflammatory cytokines can fuel the shedding and the
26 procoagulant properties of MPs. Stimulation of endothelial cells causes shedding of
27 MPs that express ultralarge von Willebrand factor multimers, which potently promote
28 the formation of platelet aggregates and increase their stability (52). Stimulation of
29 monocytes with endotoxin results in the release of TF expressing MPs (53).
30 Accordingly, administration of endotoxin to mice (54) or humans (55) results in the
31 appearance of TF bearing MPs in the circulation, and a variety of studies have
32 reported increased circulating levels of MPs of various cellular origin in patients with
33 sepsis (56-58).

34

1 A recent investigation conducted in patients with septic shock found that while total
2 MP levels were high regardless of the presence of DIC, endothelial and leukocyte-
3 derived MPs positively correlated with DIC status (59). The functional relevance of
4 MPs has been demonstrated in a number of in vivo transfer studies. Infusion of MPs
5 harvested from septic rodents reproduced part of the septic host response in healthy
6 animals (60). Similarly, administration of MPs from septic patients induced
7 differential effects in different organs of healthy mice, which at least in part mimicked
8 the organ dysfunction observed in patients with septic shock (61). Conversely,
9 inhibition of MP release through transgenic overexpression of calpastatin, a specific
10 inhibitor of calpain - a protease that plays an essential role in MP release, attenuated
11 the systemic proinflammatory response and DIC in mice with polymicrobial
12 abdominal sepsis by reducing the number of circulating procoagulant MPs (62). It
13 should be noted that MPs are able to develop immunoprotective properties in animal
14 models of sepsis, as they can explore antimicrobial activity, entrap bacteria, and
15 prevent their dissemination from the local focus of infection (63). In addition,
16 increased circulating MPs have been shown to diminish vascular hyporeactivity
17 complications in endotoxin-treated mice (58). It has been therefore suggested that
18 MPs have a beneficial effects during the early phase of sepsis (64).

19 It is also important to note that MPs have anticoagulant potential. Indeed, anionic
20 phospholipids exposed by MPs can not only assist in the assembly of procoagulant
21 enzyme complexes, but also promote the association of anticoagulant proteins,
22 including TFPI, thrombomodulin, EPCR and protein S. APC can induce MPs from
23 endothelial cells, which support efficient inactivation of factors Va and VIIa
24 facilitated by EPCR expressed by MPs. The release of antocoagulant MPs required
25 both APC and PAR1 active sites and could also be observed on monocyte-derived
26 MPs (65). Several cytoprotective effects linked to APC could be induced by APC
27 positive MPs in vitro (66). Moreover, evidence indicates that the infusion of
28 recombinant human APC, until recently a registered drug for the treatment of severe
29 sepsis, results in an increase in circulating APC positive MPs, suggesting that part of
30 the in vivo effects of APC may be mediated by anticoagulant and cytoprotective MPs
31 (67).

32 33 **Coagulation and anticoagulation during systemic and local infection**

1 Severe infection can lead to an injurious host response and tissue injury, resulting in
2 the clinical syndrome generally referred to as sepsis (8). The procoagulant response to
3 sepsis is characterized by enhanced coagulation together with impaired anticoagulant
4 mechanisms (68). The main route by which infection and inflammation initiate
5 coagulation is via TF. Indeed, inhibition of the TF/factor VIIa pathway in humans and
6 non-human primates strongly reduced activation of the coagulation system after
7 infusion of endotoxin or bacteria, while in lethal primate sepsis TF inhibition in
8 addition prevented multiple organ failure and mortality (68). In accordance, mice with
9 very low TF expression demonstrated diminished coagulation, inflammation and
10 mortality upon administration of high dose endotoxin (69).

11 The tendency towards enhanced thrombus formation during severe infection is further
12 increased due to impaired functioning of the three main anticoagulant pathways, *i.e.*,
13 antithrombin, TFPI and the protein C system (68). The regulatory function of the
14 endogenous protein C system in infection has been demonstrated in a variety of
15 studies (70). Inhibition of protein C activation aggravated the response to *Escherichia*
16 *coli* and converted a sublethal model into a lethal DIC-associated model (71).
17 Similarly, baboons treated with an anti-EPCR monoclonal antibody displayed an
18 exacerbation of a sublethal *Escherichia coli* infection to lethal sepsis with massive
19 coagulation activation (72). Notably, the anticoagulant effects of APC are not
20 essential for prevention of lethality in endotoxemic or septic mice: recombinant APC
21 mutants with selective cytoprotective properties (and almost no anticoagulant effects)
22 were as protective against lethality as wild-type APC (73). Of interest, recombinant
23 APC protected mice against endotoxin-induced lethality by an effect on EPCR and
24 PAR1 in hematopoietic cells (74). By contrast, hematopoietic EPCR deficiency did
25 not increase the susceptibility of mice to endotoxin (74, 75), indicating that the effects
26 of pharmacological doses of (exogenous) recombinant APC on immune cells may be
27 different from the effects of endogenous APC.

28 Local infection results in hemostatic alterations at the site of the infection that are
29 remarkably similar to those found in the circulation during systemic infection; this has
30 particularly been well-studied in pneumonia (76). Patients with respiratory tract
31 infections demonstrate enhanced activation of coagulation in their bronchoalveolar
32 space together with locally impaired anticoagulant mechanisms (77-79). Mouse
33 studies have revealed the important role of TF in pulmonary coagulation during
34 bacterial pneumonia (79, 80). Interference with local hemostasis has differential

1 effects on the outcome of experimental pneumonia. In accordance with finding after
2 intravenous infusion of *Escherichia coli* (71), inhibition of endogenous protein C
3 worsened survival, increased coagulation activation, facilitated bacterial growth and
4 dissemination and enhanced the inflammatory response during pneumonia-derived
5 sepsis caused by *Burkholderia pseudomallei*, the causative agent of melioidosis (81).
6 Intriguingly, transgenic overexpression of APC also resulted in enhanced
7 susceptibility to *Burkholderia pseudomallei* infection, as evidenced by a strongly
8 increased mortality accompanied by enhanced bacterial loads and increased
9 inflammation, in spite of attenuated coagulation (82), suggesting that while low
10 endogenous APC levels are essential for an adequate host defense, sustained high
11 APC concentrations are harmful. In support of a potential detrimental effect of APC,
12 mice with transgenic overexpression of EPCR, which is expected to enhance APC
13 generation, showed an impaired host defense during pneumonia caused by either
14 *Streptococcus pneumoniae* (83) or *Burkholderia pseudomallei* (84). Clearly, the exact
15 role of local coagulation and anticoagulation during localized infections requires
16 further research.

18 **Fibrinolysis**

19 Haemostasis is controlled by the fibrinolytic system, which generates plasmin to
20 degrade fibrin clots. Plasmin is generated from the zymogen protein plasminogen by
21 different proteases, in particular tissue-type plasminogen activator (t-PA) and
22 urokinase-type (u-)PA. Other enzymes that can covert plasminogen into plasmin
23 include factor XIIa and kallikrein, thereby linking the contact system with fibrinolysis
24 (85). Besides plasmin, other proteases can degrade fibrin, especially neutrophil
25 elastase, generating cross-linked fibrin fragments that are different from those
26 produced by plasmin. Inhibition of the fibrinolytic system occurs at the level of
27 plasminogen activation by plasminogen activator inhibitors (especially plasminogen
28 activator inhibitor type I or PAI-1), or at the level of plasmin activity by circulating
29 protease inhibitors, of which α 2-antiplasmin is the most important. Fibrinolysis is
30 further regulated by thrombin-activatable fibrinolysis inhibitor (TAFI), which is
31 activated by thrombin and the thrombin-thrombomodulin complex on endothelial
32 cells (86). Activated TAFI inhibits fibrinolysis by removing C-terminal lysine and
33 arginine residues from partially degraded fibrin, thereby inhibiting the high-affinity

1 binding of plasminogen to fibrin and the subsequent facilitated conversion into the
2 active protease plasmin.

3 Induction of systemic inflammation by either bacteria, bacterial products or
4 proinflammatory cytokines is associated with a transient activation of the fibrinolytic
5 system characterized by a brisk rise in plasminogen activator activity in the
6 circulation, which is subsequently shut off by the systemic appearance of PAI-1 (87).
7 Similar observations have been done in baboons with lethal bacteremia and human
8 sepsis, the net result being suppression of fibrinolysis. While the original assumption
9 was that the fibrinolytic response represents a reaction to the formation of thrombin
10 and fibrin under these conditions, several lines of evidence support the fact that the
11 procoagulant and the fibrinolytic response to systemic inflammation at least in part
12 are induced independently. In humans and nonhuman primates infusion of endotoxin
13 or *Escharichia coli* caused a rapid and transient activation of the fibrinolytic system,
14 as indicated by a marked increase in the plasma concentrations of t-PA, that preceded
15 the activation of the coagulation system (87). In addition, abrogation of coagulation
16 by inhibition of TF or factor VIIa did not affect activation of fibrinolysis during
17 human or primate endotoxemia (87-89). Finally, inhibition of plasmin generation by
18 tranexamic acid did not impact on the procoagulant response to intravenous endotoxin
19 in healthy humans (90). In experimental endotoxemia the fibrinolytic response is
20 dependent on endotoxin-induced tumor necrosis factor (TNF)- α release, as reflected
21 by a strongly inhibited release of both t-PA and PAI-1 in humans and primates
22 injected with endotoxin and treated with a neutralizing anti-TNF- α antibody; this
23 intervention does not influence activation of the coagulation (91, 92). Thus, at least in
24 these systemic challenge models the fibrinolytic response is not directly linked to the
25 clotting cascade.

26 Impaired fibrinolysis and as a consequence thereof, inadequate fibrin removal are
27 likely to contribute to the development of microvascular thrombosis in sepsis (87).
28 Indeed, the functional relevance of the fibrinolytic system for inflammation-induced
29 coagulation in sepsis has been shown by experiments in genetically modified mice,
30 showing that t-PA and u-PA deficient mice challenged with endotoxin have increased
31 fibrin deposition in their organs compared with wild type mice, while the opposite
32 was true for PAI-1 deficient mice (93). In infection models, components of the
33 fibrinolytic system have been shown to impact on host response pathways distinct
34 from fibrinolysis. While elevated elevated circulating PAI-1 levels are highly

1 predictive for an unfavorable outcome in sepsis patients (87), investigations using
2 PAI-1 deficient mice and mice with transiently enhanced expression of PAI-1 have
3 pointed to a protective rather than a detrimental role of this mediator in severe Gram-
4 negative pneumonia and sepsis (94). PAI-1 deficiency impaired host defense during
5 *Klebsiella* pneumonia and sepsis as reflected by enhanced lethality and increased
6 bacterial growth and dissemination in mice with a targeted deletion of the *pai-1* gene.
7 Conversely, transgenic overexpression of PAI-1 in the lung using a replication
8 defective adenoviral vector markedly improved host defense against *Klebsiella*
9 pneumonia and sepsis (94). PAI-1 deficiency also impaired host defense in
10 experimental pneumococcal pneumonia (95) and Gram-negative sepsis caused by
11 *Burkholderia pseudomallei* (96). Likewise, deficiency of the other main inhibitor of
12 fibrinolysis α 2-antiplasmin resulted in a strongly disturbed host response during
13 *Burkholderia pseudomallei* sepsis, as reflected by enhanced bacterial growth and
14 dissemination, exaggerated systemic inflammation and coagulation, increased distant
15 organ injury, and enhanced lethality (97). Remarkably, t-PA may in some infection
16 models also improve host defense: tPA deficient mice had an impaired defense after
17 infection with either *Escherichia coli* (98) or *Burkholderia pseudomallei* (99), as
18 indicated by higher bacterial loads and a reduced survival. In *Escherichia coli* sepsis,
19 the protective function of t-PA was independent of its capacity to convert
20 plasminogen into plasmin since plasminogen gene deficient mice were
21 indistinguishable from wild-type mice in this model (98). u-PA and its receptor (u-
22 PAR) are involved in cell migration. u-PAR mediates leukocyte adhesion to the
23 vascular wall and components of the extracellular matrix and the expression of u-PAR
24 on leukocytes is strongly associated with their migratory capacity (100). Experiments
25 in u-PAR deficient mice have shown the relevance of this receptor for the regulation
26 of the inflammatory response to infection; for example, u-PAR (but not u-PA)
27 deficient animals demonstrated a strongly diminished neutrophil influx into to lungs
28 after induction of bacterial pneumonia (101).

29 Some pathogens can activate plasminogen by producing plasminogen receptors and
30 plasminogen activation by complex formation or proteases, and/or by binding
31 plasminogen at their surface with subsequent activation by host-derived t-PA and u-
32 PA (102). Plasmin expressed at the bacterial cell surface can be used by bacteria for
33 proteolytic degradation of extracellular matrix components, thereby facilitating
34 bacterial dissemination to distant organs. Bacteria can also produce plasminogen

1 activators, *e.g.*, streptokinase produced by group A, C and G streptococci, and Pla
2 produced by *Yersinia pestis* (102). In addition, several glycolytic enzymes expressed
3 by bacteria interact with plasmin(ogen). Discussion of the impact of distinct bacterial
4 enzymes on the virulence of various micro-organisms is beyond the scope of this
5 review (see (102)).

6 TAFI plays a role in the host response to infection by a mechanism that likely is not
7 linked to its presumptive function as a natural inhibitor of fibrinolysis. TAFI deficient
8 mice did not show differences in *Escherichia coli*-induced activation of coagulation
9 or fibrinolysis in vivo, as measured by plasma levels of thrombin-antithrombin
10 complexes and D-dimer and the extent of fibrin depositions in lung and liver tissues;
11 however, TAFI deficient mice were protected from liver necrosis as indicated by
12 histopathology and clinical chemistry (103).

14 **Conclusions**

15 Recent years have shown that coagulation is much more than a glue that seals an
16 injured blood vessel. While it has been known for a long time that its systemic
17 activation can lead to devastating conditions such as disseminated intravascular
18 coagulation with high mortality rates, an important role of the coagulation system in
19 the early host response to infectious diseases has been only recently begun to be
20 appreciated. The profound knowledge about the molecular mechanisms involved in
21 these processes may help to develop novel therapeutic strategies that not only
22 prevents a systemic induction of the coagulation cascade, but also help to eliminate to
23 the pathogen at a very early time point of the disease progression.

1 **Acknowledgements**

2 This work was supported in part by the foundations of Alfred Österlund, Crafoord,
3 Greta and Johan Kock, Knut and Alice Wallenberg Foundation, Ragnar Söderberg
4 Foundation, the Medical Faculty, Lund University, the Swedish Foundation for
5 Strategic Research, and the Swedish Research Council.

6

7 **Conflict of interest disclosure**

8 The authors declare no competing financial interests.

References:

1. Versteeg HH, Heemskerk JW, Levi M, et al. New fundamentals in hemostasis. *Physiol Rev* 2013 Jan;93(1):327-58.
2. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. *Infect Immun* 2002 Dec;70(12):6524-33.
3. Frick IM, Akesson P, Herwald H, et al. The contact system--a novel branch of innate immunity generating antibacterial peptides. *Embo J* 2006 Nov 29;25(23):5569-78.
4. Kirschenbaum LA, McKevitt D, Rullan M, et al. Importance of platelets and fibrinogen in neutrophil-endothelial cell interactions in septic shock. *Crit Care Med* 2004 Sep;32(9):1904-9.
5. Shpacovitch V, Feld M, Hollenberg MD, et al. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. *J Leukoc Biol* 2008 Jun;83(6):1309-22.
6. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. *Nat Rev Immunol* 2013 Jan;13(1):34-45.
7. van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. *Current vascular pharmacology* 2012 Sep;10(5):632-8.
8. Angus DC, van der Poll T. Severe sepsis and septic shock. *N Engl J Med* 2013 Aug 29;369(9):840-51.
9. Breitenstein A, Camici GG, Tanner FC. Tissue factor: beyond coagulation in the cardiovascular system. *Clinical science* 2010 Feb;118(3):159-72.
10. Rao LV, Pendurthi UR. Regulation of tissue factor coagulant activity on cell surfaces. *J Thromb Haemost* 2012 Sep 24.
11. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. *Proc Natl Acad Sci U S A* 1990 Sep;87(18):6934-8.
12. Aberg M, Siegbahn A. Tissue factor non-coagulant signaling - molecular mechanisms and biological consequences with a focus on cell migration and apoptosis. *J Thromb Haemost* 2013 May;11(5):817-25.
13. Rottingen JA, Enden T, Camerer E, et al. Binding of human factor VIIa to tissue factor induces cytosolic Ca²⁺ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. *J Biol Chem* 1995 Mar 3;270(9):4650-60.
14. van den Hengel LG, Versteeg HH. Tissue factor signaling: a multi-faceted function in biological processes. *Front Biosci (Schol Ed)* 2011;3:1500-10.
15. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. *Proc Natl Acad Sci U S A* 2000 May 9;97(10):5255-60.
16. van den Berg YW, van den Hengel LG, Myers HR, et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. *Proc Natl Acad Sci U S A* 2009 Nov 17;106(46):19497-502.
17. Chu AJ. Tissue factor mediates inflammation. *Arch Biochem Biophys* 2005 Aug 15;440(2):123-32.
18. Srinivasan R, Bogdanov VY. Splice variants of Tissue Factor and integrin-mediated signaling. *Thromb Res* 2012 May;129 Suppl 2:S34-7.
19. Luo D, Szaba FM, Kummer LW, et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium *Yersinia enterocolitica*. *J Immunol* 2011 Aug 15;187(4):1866-76.

20. Papareddy P, Kalle M, Kasetty G, et al. C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. *J Biol Chem* 2010 Sep 3;285(36):28387-98.
21. Papareddy P, Kalle M, Sorensen OE, et al. Tissue factor pathway inhibitor 2 is found in skin and its C-terminal region encodes for antibacterial activity. *PLoS One* 2012;7(12):e52772.
22. Chand HS, Foster DC, Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. *Thromb Haemost* 2005 Dec;94(6):1122-30.
23. Hisaka T, Lardeux B, Lamireau T, et al. Expression of tissue factor pathway inhibitor-2 in murine and human liver regulation during inflammation. *Thromb Haemost* 2004 Mar;91(3):569-75.
24. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. *Crit Care* 2003 Feb;7(1):23-38.
25. Nickel KF, Renne T. Crosstalk of the plasma contact system with bacteria. *Thromb Res* 2012 Oct;130 Suppl 1:S78-83.
26. Frick IM, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. *Thromb Haemost* 2007 Sep;98(3):497-502.
27. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. *Pharmacol Rev* 2005 Mar;57(1):27-77.
28. Monteiro AC, Schmitz V, Svensjo E, et al. Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by *Trypanosoma cruzi*. *J Immunol* 2006 Nov 1;177(9):6325-35.
29. Passos GF, Fernandes ES, Campos MM, et al. Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. *J Immunol* 2004 Feb 1;172(3):1839-47.
30. Nordahl EA, Rydengard V, Morgelin M, et al. Domain 5 of high molecular weight kininogen is antibacterial. *J Biol Chem* 2005 Oct 14;280(41):34832-9.
31. Cagliani R, Forni D, Riva S, et al. Evolutionary analysis of the contact system indicates that kininogen evolved adaptively in mammals and in human populations. *Molecular biology and evolution* 2013 Jun;30(6):1397-408.
32. Hoffman M, Monroe DM, 3rd. A cell-based model of hemostasis. *Thromb Haemost* 2001 Jun;85(6):958-65.
33. Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. *Arterioscler Thromb Vasc Biol* 2005 Jul;25(7):1311-20.
34. Shrivastava S, McVey JH, Dorling A. The interface between coagulation and immunity. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2007 Mar;7(3):499-506.
35. Esmon CT. Protein C anticoagulant system--anti-inflammatory effects. *Semin Immunopathol* 2012 Jan;34(1):127-32.
36. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. *Nat Med* 2009 Nov;15(11):1318-21.
37. Williams SC. After Xigris, researchers look to new targets to combat sepsis. *Nat Med* 2012 Jul;18(7):1001.

- 1 38. Kasetty G, Papareddy P, Kalle M, et al. The C-terminal sequence of several
2 human serine proteases encodes host defense functions. *J Innate Immun*
3 2011;3(5):471-82.
- 4 39. Kalle M, Papareddy P, Kasetty G, et al. Host defense peptides of thrombin
5 modulate inflammation and coagulation in endotoxin-mediated shock and
6 *Pseudomonas aeruginosa* sepsis. *PLoS One* 2012;7(12):e51313.
- 7 40. Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic
8 development to blood coagulation. *Trends Biochem Sci* 2002 Feb;27(2):67-74.
- 9 41. Hanington PC, Zhang SM. The primary role of fibrinogen-related proteins in
10 invertebrates is defense, not coagulation. *J Innate Immun* 2011;3(1):17-27.
- 11 42. Pahlman LI, Morgelin M, Kasetty G, et al. Antimicrobial activity of
12 fibrinogen and fibrinogen-derived peptides--a novel link between coagulation and
13 innate immunity. *Thromb Haemost* 2013 May;109(5):930-9.
- 14 43. Forsyth CB, Solovjov DA, Ugarova TP, et al. Integrin alpha(M)beta(2)-
15 mediated cell migration to fibrinogen and its recognition peptides. *J Exp Med* 2001
16 May 21;193(10):1123-33.
- 17 44. Loof TG, Morgelin M, Johansson L, et al. Coagulation, an ancestral serine
18 protease cascade, exerts a novel function in early immune defense. *Blood* 2011 Sep
19 1;118(9):2589-98.
- 20 45. Burnier L, Fontana P, Kwak BR, et al. Cell-derived microparticles in
21 haemostasis and vascular medicine. *Thromb Haemost* 2009 Mar;101(3):439-51.
- 22 46. Norling LV, Dalli J. Microparticles are novel effectors of immunity. *Curr*
23 *Opin Pharmacol* 2013 Aug;13(4):570-5.
- 24 47. Berckmans RJ, Nieuwland R, Boing AN, et al. Cell-derived microparticles
25 circulate in healthy humans and support low grade thrombin generation. *Thromb*
26 *Haemost* 2001 Apr;85(4):639-46.
- 27 48. Oehmcke S, Morgelin M, Malmstrom J, et al. Stimulation of blood
28 mononuclear cells with bacterial virulence factors leads to the release of pro-
29 coagulant and pro-inflammatory microparticles. *Cell Microbiol* 2012 Jan;14(1):107-
30 19.
- 31 49. Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle
32 membranes have 50- to 100-fold higher specific procoagulant activity than activated
33 platelets. *Thromb Haemost* 2007 Mar;97(3):425-34.
- 34 50. Dasgupta SK, Abdel-Monem H, Niravath P, et al. Lactadherin and clearance
35 of platelet-derived microvesicles. *Blood* 2009 Feb 5;113(6):1332-9.
- 36 51. Ramacciotti E, Hawley AE, Farris DM, et al. Leukocyte- and platelet-derived
37 microparticles correlate with thrombus weight and tissue factor activity in an
38 experimental mouse model of venous thrombosis. *Thromb Haemost* 2009
39 Apr;101(4):748-54.
- 40 52. Jy W, Jimenez JJ, Mauro LM, et al. Endothelial microparticles induce
41 formation of platelet aggregates via a von Willebrand factor/ristocetin dependent
42 pathway, rendering them resistant to dissociation. *J Thromb Haemost* 2005
43 Jun;3(6):1301-8.
- 44 53. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation is a possible
45 mechanism for dissemination of membrane-associated procoagulant activities and
46 adhesion molecules after stimulation by lipopolysaccharide. *J Immunol* 1994 Oct
47 1;153(7):3245-55.
- 48 54. Wang JG, Manly D, Kirchhofer D, et al. Levels of microparticle tissue factor
49 activity correlate with coagulation activation in endotoxemic mice. *J Thromb*
50 *Haemost* 2009 Jul;7(7):1092-8.

- 1 55. Aras O, Shet A, Bach RR, et al. Induction of microparticle- and cell-
2 associated intravascular tissue factor in human endotoxemia. *Blood* 2004 Jun
3 15;103(12):4545-53.
- 4 56. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and
5 procoagulant properties of microparticles in meningococcal sepsis. *Blood* 2000 Feb
6 1;95(3):930-5.
- 7 57. Soriano AO, Jy W, Chirinos JA, et al. Levels of endothelial and platelet
8 microparticles and their interactions with leukocytes negatively correlate with organ
9 dysfunction and predict mortality in severe sepsis. *Crit Care Med* 2005
10 Nov;33(11):2540-6.
- 11 58. Mostefai HA, Meziani F, Mastronardi ML, et al. Circulating microparticles
12 from patients with septic shock exert protective role in vascular function. *Am J Respir*
13 *Crit Care Med* 2008 Dec 1;178(11):1148-55.
- 14 59. Delabranche X, Boisrame-Helms J, Asfar P, et al. Microparticles are new
15 biomarkers of septic shock-induced disseminated intravascular coagulopathy.
16 *Intensive Care Med* 2013 Oct;39(10):1695-703.
- 17 60. Mortaza S, Martinez MC, Baron-Menguy C, et al. Detrimental hemodynamic
18 and inflammatory effects of microparticles originating from septic rats. *Crit Care Med*
19 2009 Jun;37(6):2045-50.
- 20 61. Mastronardi ML, Mostefai HA, Meziani F, et al. Circulating microparticles
21 from septic shock patients exert differential tissue expression of enzymes related to
22 inflammation and oxidative stress. *Crit Care Med* 2011 Jul;39(7):1739-48.
- 23 62. Zafrani L, Gerotziafas G, Byrnes C, et al. Calpastatin controls polymicrobial
24 sepsis by limiting procoagulant microparticle release. *Am J Respir Crit Care Med*
25 2012 Apr 1;185(7):744-55.
- 26 63. Oehmcke S, Westman J, Malmstrom J, et al. A novel role for pro-coagulant
27 microvesicles in the early host defense against streptococcus pyogenes. *PLoS Pathog*
28 2013;9(8):e1003529.
- 29 64. Reid VL, Webster NR. Role of microparticles in sepsis. *Br J Anaesth* 2012
30 Oct;109(4):503-13.
- 31 65. Perez-Casal M, Downey C, Fukudome K, et al. Activated protein C induces
32 the release of microparticle-associated endothelial protein C receptor. *Blood* 2005 Feb
33 15;105(4):1515-22.
- 34 66. Perez-Casal M, Downey C, Cutillas-Moreno B, et al. Microparticle-associated
35 endothelial protein C receptor and the induction of cytoprotective and anti-
36 inflammatory effects. *Haematologica* 2009 Mar;94(3):387-94.
- 37 67. Perez-Casal M, Thompson V, Downey C, et al. The clinical and functional
38 relevance of microparticles induced by activated protein C treatment in sepsis. *Crit*
39 *Care* 2011;15(4):R195.
- 40 68. Levi M, van der Poll T. Inflammation and coagulation. *Crit Care Med* 2010
41 Feb;38(2 Suppl):S26-34.
- 42 69. Pawlinski R, Pedersen B, Schabbauser G, et al. Role of tissue factor and
43 protease-activated receptors in a mouse model of endotoxemia. *Blood* 2004 Feb
44 15;103(4):1342-7.
- 45 70. Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue
46 inflammation and injury: pathogenic role and therapeutic implications. *Blood* 2010
47 Feb 11;115(6):1121-30.
- 48 71. Taylor FB, Jr., Chang A, Esmon CT, et al. Protein C prevents the
49 coagulopathic and lethal effects of *Escherichia coli* infusion in the baboon. *J Clin*
50 *Invest* 1987;79(3):918-25.

- 1 72. Taylor FB, Jr., Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell
2 protein C receptor aids in host defense against Escherichia coli sepsis. *Blood* 2000
3 Mar 1;95(5):1680-6.
- 4 73. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis
5 mortality reduction by non-anticoagulant activated protein C. *J Exp Med* 2007 Oct
6 1;204(10):2439-48.
- 7 74. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD8+
8 dendritic cells to reduce the mortality of endotoxemia in mice. *J Clin Invest* 2010 Sep
9 1;120(9):3167-78.
- 10 75. Zheng X, Li W, Song Y, et al. Non-hematopoietic EPCR regulates the
11 coagulation and inflammatory responses during endotoxemia. *J Thromb Haemost*
12 2007 Jul;5(7):1394-400.
- 13 76. Levi M, Schultz MJ, Rijneveld AW, et al. Bronchoalveolar coagulation and
14 fibrinolysis in endotoxemia and pneumonia. *Crit Care Med* 2003 Apr;31(4
15 Suppl):S238-42.
- 16 77. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by
17 enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia.
18 Comparison with the acute respiratory distress syndrome. *Am J Respir Crit Care Med*
19 2000 Feb;161(2 Pt 1):454-62.
- 20 78. Choi G, Schultz MJ, Levi M, et al. Protein C in pneumonia. *Thorax* 2005
21 Aug;60(8):705-6.
- 22 79. Rijneveld AW, Weijer S, Bresser P, et al. Local activation of the tissue factor-
23 factor VIIa pathway in patients with pneumonia and the effect of inhibition of this
24 pathway in murine pneumococcal pneumonia. *Crit Care Med* 2006 Jun;34(6):1725-
25 30.
- 26 80. Van Den Boogaard FE, Brands X, Schultz MJ, et al. Recombinant human
27 tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and
28 antimicrobial effects in murine pneumococcal pneumonia. *J Thromb Haemost* 2011
29 Jan;9(1):122-32.
- 30 81. Kager LM, Wiersinga WJ, Roelofs JJ, et al. Endogenous protein C has a
31 protective role during Gram-negative pneumosepsis (melioidosis). *J Thromb Haemost*
32 2013 Feb;11(2):282-92.
- 33 82. Kager LM, Wiersinga WJ, Roelofs JJ, et al. Overexpression of activated
34 protein C is detrimental during severe experimental gram-negative sepsis
35 (melioidosis). *Crit Care Med* 2013 Oct;41(10):e266-74.
- 36 83. Schouten M, de Boer JD, Kager LM, et al. The endothelial protein C receptor
37 impairs the antibacterial response in murine pneumococcal pneumonia and sepsis.
38 *Thromb Haemost* 2014 Jan 9;111(5).
- 39 84. Kager LM, Schouten M, Wiersinga WJ, et al. Overexpression of the
40 endothelial protein C receptor is detrimental during pneumonia-derived gram-
41 negative sepsis (Meloidosis). *PLoS neglected tropical diseases* 2013 Jul;7(7):e2306.
- 42 85. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. *Semin Thromb*
43 *Hemost* 2011 Jun;37(4):375-81.
- 44 86. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the
45 nexus of fibrinolysis and inflammation. *Thromb Res* 2012 Mar;129(3):314-9.
- 46 87. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in
47 disseminated intravascular coagulation. *Semin Thromb Hemost* 2001;27(6):639-51.
- 48 88. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced
49 activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-
50 tissue factor antibody in chimpanzees. *J Clin Invest* 1994;93(1):114-20.

89. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. *Blood* 2000;95(4):1124-9.
90. Renckens R, Weijer S, de Vos AF, et al. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. *Arterioscler Thromb Vasc Biol* 2004 Mar;24(3):483-8.
91. van der Poll T, Levi M, van Deventer SJ, et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. *Blood* 1994;83(2):446-51.
92. van der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. *Blood* 1997;89(10):3727-34.
93. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. *J Clin Invest* 1996 Jun 1;97(11):2440-51.
94. Renckens R, Roelofs JJ, Bonta PI, et al. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. *Blood* 2007 Feb 15;109(4):1593-601.
95. Lim JH, Stirling B, Derry J, et al. Tumor suppressor CYLD regulates acute lung injury in lethal *Streptococcus pneumoniae* infections. *Immunity* 2007 Aug;27(2):349-60.
96. Kager LM, Wiersinga WJ, Roelofs JJ, et al. Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis). *J Thromb Haemost* 2011 Oct;9(10):2020-8.
97. Kager LM, Weehuizen TA, Wiersinga WJ, et al. Endogenous alpha2-Antiplasmin Is Protective during Severe Gram-Negative Sepsis (Melioidosis). *Am J Respir Crit Care Med* 2013 Oct 15;188(8):967-75.
98. Renckens R, Roelofs JJ, Florquin S, et al. Endogenous tissue-type plasminogen activator is protective during *Escherichia coli*-induced abdominal sepsis in mice. *J Immunol* 2006 Jul 15;177(2):1189-96.
99. Kager LM, Wiersinga WJ, Roelofs JJ, et al. Endogenous tissue-type plasminogen activator impairs host defense during severe experimental Gram-negative sepsis (melioidosis)*. *Crit Care Med* 2012 Jul;40(7):2168-75.
100. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. *Trends Immunol* 2004 Aug;25(8):450-5.
101. Rijneveld AW, Levi M, Florquin S, et al. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. *J Immunol* 2002;168(7):3507-11.
102. Bergmann S, Hammerschmidt S. Fibrinolysis and host response in bacterial infections. *Thromb Haemost* 2007 Sep;98(3):512-20.
103. Renckens R, Roelofs JJ, ter Horst SA, et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. *J Immunol* 2005 Nov 15;175(10):6764-71.

1 **Figure legend**

2 Figure 1: **The disturbed hemostatic balance in sepsis.** Sepsis is associated with
3 microvascular thrombosis due to concurrent activation of coagulation (mediated by
4 tissue factor) and impairment of anticoagulant mechanisms as a consequence of
5 reduced activity of endogenous anticoagulant pathways mediated by activated protein
6 C (APC), antithrombin and tissue factor pathway inhibitor (TFPI), plus impaired
7 fibrinolysis due to enhanced release of plasminogen activator inhibitor type I (PAI-1).
8 The capacity to generate activated protein C is impaired at least in part due to reduced
9 expression of the endothelial receptors thrombomodulin (TM) and the endothelial
10 protein C receptor (EPCR). Thrombus formation is further facilitated by neutrophil
11 extracellular traps (NETs) released from dying neutrophils. Loss of endothelial barrier
12 function is at least in part caused by a disturbed balance between sphingosine 1
13 phosphate receptor 1 (S1P1) and S1P3 within the vascular wall at least in part due
14 preferential induction of S1P3 via protease activated receptor 1 (PAR1) secondary to
15 a reduced APC/thrombin ratio.

Table1: Procoagulant factors and their role in innate immunity

protein/peptide	function	reference
tissue factor	activation of PAR2 activation of mitogen activated protein kinase family	(1) (2)
tissue factor pathway inhibitor 1/2	antimicrobial activity	(3, 4)
contact system factors	pattern recognition molecules	(5)
high molecular weight kininogen	precursor of peptides with antimicrobial activity	(6, 7)
bradykinin	inflammatory mediator (chronic)	(8)
des-Arg ⁹ -bradykinin	inflammatory mediator (acute)	(8)
factor Xa	activation of PAR receptors precursor of peptides with antimicrobial activity	(9) (10)
thrombin	activation of PAR receptors precursor of peptides with antimicrobial activity	(9) (3)
activated protein C	activation of PAR1 receptor	(11)
factor XIIIa	immobilization of bacteria inside a clot	(12)
microparticles (MPs)	antimicrobial activity and entrapment of bacteria diminish vascular hyporeactivity complications	(63) (58)
neutrophil extracellular traps (NETs)	activation of the contact system adhesion, activation, and aggregation of platelets	(13) (14)
TAFI	conversion of bradykinin to des-Arg ⁹ -bradykinin escaping from fibrin-mediated physical entrapment	(110) (111)

Coagulation ↑

Anti-coagulation ↓

Endothelial cell

Tissue factor ↑

TFPI ↓

Antithrombin ↓

TM ↓ EPCR ↓

Protein C (↓)

APC ↓

Fibrinolysis ↓

PAI-1 ↑

APC ↓ - thrombin ↑

PAR1

S1P3/S1P1 ↑

Thrombosis

Monocyte

NETs with trapped platelets

Neutrophil

